Roles of sulfated and nonsulfated glycosaminoglycans in cancer growth and progression-therapeutic implications

Extracellular Matrix: Pathobiology and Signaling

Volumn , Issue , 2012, Pages 66-83

  Nikitovic, Dragana ^a   Tzanakakis, George N ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901418609     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (140)

1. Abad Rico, J. I., Llau Pitarch, J. V., and Rocha, E. (2010). Overview of venous thromboembolism. Drugs 70 (Suppl. 2), 3-10.
2. Aguiar, C. B., Lobao-Soares, B., Alvarez-Silva, M., and Trentin, A. G. (2005). Glycosaminoglycans modulate C6 glioma cell adhesion to extracellular matrix components and alter cell proliferation and cell migration. BMC Cell Biol 6, 31.
3. Akl, E. A., Gunukula, S., Barba, M., et al. (2011). Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev CD006652.
4. Allen, B. L., Filla, M. S., and Rapraeger, A. C. (2001). Role of heparan sulfate as a tissuespecific regulator of FGF-4 and FGF receptor recognition. J Cell Biol 155, 845-858.
5. Ang, L. C., Zhang, Y., Cao, L., et al. (1999). Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 58, 597-605.
6. Antonio, J. D. S., and Iozzo, R. V. (2001). Glycosaminoglycans: structure and biological functions. eLS doi: 10.1038/npg.els.0000704.
7. Anttila, M. A., Tammi, R. H., Tammi, M. I., Syrjanen, K. J., Saarikoski, S. V., and Kosma, V. M. (2000). High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60, 150-155.
8. Asada, M., Shinomiya, M., Suzuki, M., et al. (2009). Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim Biophys Acta 1790, 40-48.
9. Auvinen, P., Tammi, R., Parkkinen, J., et al. (2000). Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156, 529-536.
10. Baggio, B., Marzaro, G., Gambaro, G., Marchini, F., Williams, H. E., and Borsatti, A. (1990). Glycosaminoglycan content, oxalate self-exchange and protein phosphorylation in erythrocytes of patients with 'idiopathic' calcium oxalate nephrolithiasis. Clin Sci (Lond) 79, 113-116.
11. Baljinnyam, E., Umemura, M., De Lorenzo, M. S., et al. (2011). Epac1 promotes melanoma metastasis via modification of heparan sulfate. Pigment Cell Melanoma Res 24 (4), 680-687.
12. Basappa, Murugan, S., Sugahara, K. N., Lee, C. M., et al. (2009). Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. Glycobiology 19, 735-742.
13. Berdiaki, A., Nikitovic, D., Tsatsakis, A., Katonis, P., Karamanos, N. K., and Tzanakakis, G. N. (2009). bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells. Biochim Biophys Acta 1790, 1258-1265.
14. Bernfield, M., Gotte, M., Park, P. W., et al. (1999). Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729-777.
15. Bishop, J. M., O'Ryan, C., and Jarvis, J. U. (2007). Social common mole-rats enhance outbreeding via extra-pair mating. Biol Lett 3, 176-179.
16. Bloushtain, N., Qimron, U., Bar-Ilan, A., et al. (2004). Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 173, 2392-2401.
17. Borsig, L., Vlodavsky, I., Ishai-Michaeli, R., Torri, G., and Vismara, E. (2011). Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia 13, 445-452.
18. Bret, C., Hose, D., Reme, T., et al. (2009). Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol 145, 350-368.
19. Burg, M., Heinemann, U., and Schmitz, D. (1998). Neuroactive steroids induce GABA(A) receptor-mediated depolarizing postsynaptic potentials in hippocampal CA1 pyramidal cells of the rat. Eur J Neurosci 10, 2880-2886.
20. Campbell, R. E., and Tanner, M. E. (1999). UDP-glucose analogues as inhibitors and mechanistic probes of UDP-glucose dehydrogenase. J Org Chem 64, 9487-9492.
21. Campoli, M., Ferrone, S., and Wang, X. (2010). Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 109, 73-121.
22. Cattaruzza, S., Schiappacassi, M., Kimata, K., Colombatti, A., and Perris, R. (2004). The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J 18, 779-781.
23. Chaffer, C. L., and Weinberg, R. A. (2011). A perspective on cancer cell metastasis. Science 331, 1559-1564.
24. Chalkiadaki, G., Nikitovic, D., Berdiaki, A., Katonis, P., Karamanos, N. K., and Tzanakakis, G. N. (2011). Heparin plays a key regulatory role via a p53/FAK-dependent signaling in melanoma cell adhesion and migration. IUBMB Life 63, 109-119.
25. Chalkiadaki, G., Nikitovic, D., Berdiaki, A., et al. (2009). Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism. Int J Biochem Cell Biol 41, 1323-1331.
26. Chen, L., and Sanderson, R. D. (2009). Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One 4, e4947.
27. Chen, Z., Jing, Y., Song, B., Han, Y., and Chu, Y. (2009). Chemically modified heparin inhibits in vitro L-selectin-mediated human ovarian carcinoma cell adhesion. Int J Gynecol Cancer. 19, 540-546.
28. Chow, G., Tauler, J., and Mulshine, J. L. (2010). Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol 485468.
29. Cortes, M., Baria, A. T., and Schwartz, N. B. (2009). Sulfation of chondroitin sulfate proteoglycans is necessary for proper Indian hedgehog signaling in the developing growth plate. Development 136, 1697-1706.
30. Couchman, J. R., Kapoor, R., Sthanam, M., and Wu, R. R. (1996). Perlecan and basement membrane-chondroitin sulfate proteoglycan (bamacan) are two basement membrane chondroitin/dermatan sulfate proteoglycans in the Engelbreth-Holm-Swarm tumor matrix. J Biol Chem 271, 9595-9602.
31. Damiens, E., El Yazidi, I., Mazurier, J., et al. (1998). Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. Eur J Cell Biol 77, 344-351.
32. Day, A. J., and Prestwich, G. D. (2002). Hyaluronan-binding proteins: tying up the giant. J Biol Chem 277, 4585-4588.
33. Deepa, S. S., Umehara, Y., Higashiyama, S., Itoh, N., and Sugahara, K. (2002). Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues. J Biol Chem 277, 43707-43716.
34. Egger, S., Chaikuad, A., Kavanagh, K. L., Oppermann, U., and Nidetzky, B. (2010). UDPglucose dehydrogenase: structure and function of a potential drug target. Biochem Soc Trans 38, 1378-1385.
35. Eisenmann, K. M., McCarthy, J. B., Simpson, M. A., et al. (1999). Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1, 507-513.
36. Engelberg, H. (1999). Actions of heparin that may affect the malignant process. Cancer 85, 257-272.
37. Esko, J. D., and Lindahl, U. (2001). Molecular diversity of heparan sulfate. J Clin Invest 108, 169-173.
38. Fidler, I. J., and Kripke, M. L. (2003). Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet 34, 23; author reply 25.
39. Folkman, J., Klagsbrun, M., Sasse, J., Wadzinski, M., Ingber, D., and Vlodavsky, I. (1988). A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 130, 393-400.
40. Folkman, J., and Shing, Y. (1992). Angiogenesis. J Biol Chem 267, 10931-10934.
41. Forsberg, E., and Kjellen, L. (2001). Heparan sulfate: lessons from knockout mice. J Clin Invest 108, 175-180.
42. Fthenou, E., Zafiropoulos, A., Katonis, P., Tsatsakis, A., Karamanos, N. K., and Tzanakakis, G. N. (2008). Chondroitin sulfate prevents platelet derived growth factor-mediated phosphorylation of PDGF-Rbeta in normal human fibroblasts severely impairing mitogenic responses. J Cell Biochem 103, 1866-1876.
43. Fthenou, E., Zafiropoulos, A., Tsatsakis, A., Stathopoulos, A., Karamanos, N. K., and Tzanakakis, G. N. (2006). Chondroitin sulfate A chains enhance platelet derived growth factor-mediated signalling in fibrosarcoma cells. Int J Biochem Cell Biol 38, 2141-2150.
44. Fthenou, E., Zong, F., Zafiropoulos, A., Dobra, K., Hjerpe, A., and Tzanakakis, G. N. (2009). Chondroitin sulfate A regulates fibrosarcoma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. In Vivo 23, 69-76.
45. Gladson, C. L. (1999). The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 58, 1029-1040.
46. Godin, D. A., Fitzpatrick, P. C., Scandurro, A. B., et al. (2000). PH20: a novel tumor marker for laryngeal cancer. Arch Otolaryngol Head Neck Surg 126, 402-404.
47. Gu, W. L., Fu, S. L., Wang, Y. X., et al. (2009). Chondroitin sulfate proteoglycans regulate the growth, differentiation and migration of multipotent neural precursor cells through the integrin signaling pathway. BMC Neurosci 10, 128.
48. Guimond, S., Maccarana, M., Olwin, B. B., Lindahl, U., and Rapraeger, A. C. (1993). Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 268, 23906-23914.
49. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
50. Harper, J. R., and Reisfeld, R. A. (1987). Cell-associated proteoglycans in human malignant melanoma. In Biology of Proteoglycans, T. N. Wight and R. P. Mecham, eds. Orlando, FL: Academic Press, pp. 345-366.
51. Hirvikoski, P., Tammi, R., Kumpulainen, E., et al. (1999). Irregular expression of hyaluronan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma. Virchows Arch 434, 37-44.
52. Ho, M., and Kim, H. (2011). Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 47, 333-338.
53. Huang, X., Kim, J. M., Kong, T. H., et al. (2009). GM-CSF inhibits glial scar formation and shows long-term protective effect after spinal cord injury. J Neurol Sci 277, 87-97.
54. Huh, J. W., Choi, M. M., Yang, S. J., Yoon, S. Y., Choi, S. Y., and Cho, S. W. (2005). Inhibition of human UDP-glucose dehydrogenase expression using siRNA expression vector in breast cancer cells. Biotechnol Lett 27, 1229-1232.
55. Hwang, E. Y., Huh, J. W., Choi, M. M., Choi, S. Y., Hong, H. N., and Cho, S. W. (2008). Inhibitory effects of gallic acid and quercetin on UDP-glucose dehydrogenase activity. FEBS Lett 582, 3793-3797.
56. Iida, J., Wilhelmson, K. L., Ng, J., et al. (2007). Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J 403, 553-563.
57. Ilan, N., Elkin, M., and Vlodavsky, I. (2006). Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38, 2018-2039.
58. Ioachim, H. L. (1976). The stromal reaction of tumors: an expression of immune surveillance. J Natl Cancer Inst 57, 465-475.
59. Iozzo, R. V., and Sanderson, R. D. (2011). Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15, 1013-1031.
60. Iozzo, R. V., and Schaefer, L. (2010). Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277 (19), 3864-3875.
61. Itano, N., Atsumi, F., Sawai, T., et al. (2002). Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc Natl Acad Sci U S A 99, 3609-3614.
62. Jacobson, A., Rahmanian, M., Rubin, K., and Heldin, P. (2002). Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer 102, 212-219.
63. Jia, J., Maccarana, M., Zhang, X., Bespalov, M., Lindahl, U., and Li, J. P. (2009). Lack of L-iduronic acid in heparan sulfate affects interaction with growth factors and cell signaling. J Biol Chem 284, 15942-15950.
64. Kalathas, D., Theocharis, D. A., Bounias, D., et al. (2009). Alterations of glycosaminoglycan disaccharide content and composition in colorectal cancer: structural and expressional studies. Oncol Rep 22, 369-375.
65. Kalathas, D., Theocharis, D. A., Bounias, D., et al. (2011a). Chondroitin synthases I, II, III and chondroitin sulfate glucuronyltransferase expression in colorectal cancer. Mol Med Report 4, 363-368.
66. Kalathas, D., Triantaphyllidou, I. E., Mastronikolis, N. S., et al. (2011b). The chondroitin/ dermatan sulfate synthesizing and modifying enzymes in laryngeal cancer: expressional and epigenetic studies. Head Neck Oncol 2, 27.
67. Karamanos, N. K., and Tzanakakis, G. N. (2012). Glycosaminoglycans: from "cellular glue" to novel therapeutical agents. Curr Opin Pharmacol 12, 220-222.
68. Karjalainen, J. M., Tammi, R. H., Tammi, M. I., et al. (2000). Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol 157, 957-965.
69. Khurana, A., Liu, P., Mellone, P., et al. (2011). HSulf-1 modulates FGF2and hypoxiamediated migration and invasion of breast cancer cells. Cancer Res 71, 2152-2161.
70. Kiewe, P., Bechrakis, N. E., Schmittel, A., et al. (2006). Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma. Ann Oncol 17, 1830-1834.
71. Kim, S. H., Turnbull, J., and Guimond, S. (2011). Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 209, 139-151.
72. Kosunen, A., Ropponen, K., Kellokoski, J., et al. (2004). Reduced expression of hyaluronan is a strong indicator of poor survival in oral squamous cell carcinoma. Oral Oncol 40, 257-263.
73. Kouvidi, K., Berdiaki, A., Nikitovic, D., et al. (2011). Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J Biol Chem 286, 38509-38520.
74. Lai, J., Chien, J., Staub, J., et al. (2003). Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278, 23107-23117.
75. Lai, J. P., Sandhu, D. S., Yu, C., et al. (2010). Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int 30, 1522-1528.
76. LaPierre, D. P., Lee, D. Y., Li, S. Z., et al. (2007). The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 67, 4742-4750.
77. Laurent, J., and Guinnepain, M. T. (1996). Hereditary angioedema with ascites. J Allergy Clin Immunol 98, 999.
78. Ledin, J., Staatz, W., Li, J. P., et al. (2004). Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem 279, 42732-42741.
79. Lee, H., Jeong, J. H., and Park, T. G. (2002). PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicity. J Control Release 79, 283-291.
80. Li, F., Shi, W., Capurro, M., and Filmus, J. (2011). Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol 192, 691-704.
81. Linhardt, R. J. (2003). 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. J Med Chem 46, 2551-2564.
82. Lo, S. L., Thike, A. A., Tan, S. Y., et al. (2011). Expression of heparan sulfate in gastric carcinoma and its correlation with clinicopathological features and patient survival. J Clin Pathol 64, 153-158.
83. Lokeshwar, V. B., Habuchi, T., Grossman, H. B., et al. (2005). Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66, 35-63.
84. Lokeshwar, V. B., Lokeshwar, B. L., Pham, H. T., and Block, N. L. (1996). Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res 56, 651-657.
85. Lundin, L., Larsson, H., Kreuger, J., et al. (2000). Selectively desulfated heparin inhibits fibro-blast growth factor-induced mitogenicity and angiogenesis. J Biol Chem 275, 24653-24660.
86. Lv, H., Yu, G., Sun, L., Zhang, Z., Zhao, X., and Chai, W. (2007). Elevate level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma. Oncology 72, 347-356.
87. Madan, A. K., Yu, K., Dhurandhar, N., Cullinane, C., Pang, Y., and Beech, D. J. (1999). Association of hyaluronidase and breast adenocarcinoma invasiveness. Oncol Rep 6, 607-609.
88. Malavaki, C. J., Theocharis, A. D., Lamari, F. N., et al. (2011). Heparan sulfate: biological significance, tools for biochemical analysis and structural characterization. Biomed Chromatogr 25, 11-20.
89. Maraveyas, A., Johnson, M. J., Xiao, Y. P., and Noble, S. (2010). Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins. Cancer Metastasis Rev 29, 777-784.
90. Martins, R. C., Lima, F. R., Werneck, C. C., Neto, V. M., and Silva, L. C. (2000). Patterns of synthesis and secretion of sulfated glycosaminoglycans in primary cortical and cerebellar astrocytes in vitro. Biol Cell 92, 421-427.
91. Matsuda, K., Maruyama, H., Guo, F., et al. (2001). Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 61, 5562-5569.
92. Monzavi-Karbassi, B., Stanley, J. S., Hennings, L., et al. (2007). Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int J Cancer 120, 1179-1191.
93. Muramatsu, T., and Muramatsu, H. (2008). Glycosaminoglycan-binding cytokines as tumor markers. Proteomics 8, 3350-3359.
94. Nakato, H., and Kimata, K. (2002). Heparan sulfate fine structure and specificity of proteoglycan functions. Biochim Biophys Acta 1573, 312-318.
95. Narita, K., Chien, J., Mullany, S. A., et al. (2007). Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem 282, 14413-14420.
96. Nikitovic, D., Assouti, M., Sifaki, M., et al. (2008). Chondroitin sulfate and heparan sulfatecontaining proteoglycans are both partners and targets of basic fibroblast growth factor-mediated proliferation in human metastatic melanoma cell lines. Int J Biochem Cell Biol 40, 72-83.
97. Nikitovic, D., Zafiropoulos, A., Katonis, P., et al. (2006). Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 58, 47-53.
98. Nikitovic, D., Zafiropoulos, A., Tzanakakis, G. N., Karamanos, N. K., and Tsatsakis, A. M. (2005). Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions. Anticancer Res 25, 2851-2856.
99. Nurcombe, V., Smart, C. E., Chipperfield, H., Cool, S. M., Boilly, B., and Hondermarck, H. (2000). The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J Biol Chem 275, 30009-30018.
100. Ohyama, C. (2008). Glycosylation in bladder cancer. Int J Clin Oncol 13, 308-313.
101. Pan, J., Qian, Y., Weiser, P., et al. (2011). Glycosaminoglycans and activated contact system in cancer patient plasmas. Prog Mol Biol Transl Sci 93, 473-495.
102. Pauli, B. U., Schwartz, D. E., Thonar, E. J., and Kuettner, K. E. (1983). Tumor invasion and host extracellular matrix. Cancer Metastasis Rev 2, 129-152.
103. Pawlowski, A., Haberman, H. F., and Menon, I. A. (1979). The effects of hyalurodinase upon tumor formation in BALB/c mice painted with 7,12-dimethylbenz-(a)anthracene. Int J Cancer 23, 105-109.
104. Pirinen, R., Tammi, R., Tammi, M., et al. (2001). Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 95, 12-17.
105. Potapenko, I. O., Haakensen, V. D., Luders, T., et al. (2010). Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol 4, 98-118.
106. Prabhakar, V., and Sasisekharan, R. (2006). The biosynthesis and catabolism of galactosaminoglycans. Adv Pharmacol 53, 69-115.
107. Pumphrey, C. Y., Theus, A. M., Li, S., Parrish, R. S., and Sanderson, R. D. (2002). Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res 62, 3722-3728.
108. Pupa, S. M., Menard, S., Forti, S., and Tagliabue, E. (2002). New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 192, 259-267.
109. Ricciardelli, C., Sakko, A. J., Stahl, J., Tilley, W. D., Marshall, V. R., and Horsfall, D. J. (2009). Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate 69, 761-769.
110. Serafino, A., Zonfrillo, M., Andreola, F., et al. (2011). CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr Cancer Drug Targets 11, 572-585.
111. Simpson, M. A., Wilson, C. M., Furcht, L. T., Spicer, A. P., Oegema, T. R., Jr., and McCarthy, J. B. (2002). Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells. J Biol Chem 277, 10050-10057.
112. Sironen, R. K., Tammi, M., Tammi, R., Auvinen, P. K., Anttila, M., and Kosma, V. M. (2011). Hyaluronan in human malignancies. Exp Cell Res 317, 383-391.
113. Smorenburg, S. M., and Van Noorden, C. J. (2001). The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53, 93-105.
114. Stallcup, W. B., and Huang, F. J. (2008). A role for the NG2 proteoglycan in glioma progression. Cell Adh Migr 2, 192-201.
115. Stern, R. (2003). Devising a pathway for hyaluronan catabolism: are we there yet? Glycobiology 13, 105R-115R.
116. Stern, R. (2008). Hyaluronidases in cancer biology. Semin Cancer Biol 18, 275-280.
117. Sugaya, N., Habuchi, H., Nagai, N., Ashikari-Hada, S., and Kimata, K. (2008). 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture. J Biol Chem 283, 10366-10376.
118. Suzuki, Y. (1992). Diagnostic criteria for human diffuse malignant mesothelioma. Acta Pathol Jpn 42, 767-786.
119. Syrokou, A., Tzanakakis, G., Tsegenidis, T., Hjerpe, A., and Karamanos, N. K. (1999). Effects of glycosaminoglycans on proliferation of epithelial and fibroblast human malignant mesothelioma cells: a structure-function relationship. Cell Prolif 32, 85-99.
120. Tátrai, P., Egedi, K., Somoracz, A., et al. (2011). Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem 58, 429-441.
121. Ten Dam, G. B., van de Westerlo, E. M., Purushothaman, A., et al. (2007). Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. Am J Pathol 171, 1324-1333.
122. Theocharis, A. D., Skandalis, S. S., Tzanakakis, G. N., and Karamanos, N. K. (2011). Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 278, 16-27.
123. Theocharis, A. D., and Theocharis, D. A. (2002). High-performance capillary electrophoretic analysis of hyaluronan and galactosaminoglycan-disaccharides in gastrointestinal carcinomas. Differential disaccharide composition as a possible tool-indicator for malignancies. Biomed Chromatogr 16, 157-161.
124. Theocharis, A. D., Tsolakis, I., Tzanakakis, G. N., and Karamanos, N. K. (2006). Chondroitin sulfate as a key molecule in the development of atherosclerosis and cancer progression. Adv Pharmacol 53, 281-295.
125. Toole, B. P., and Hascall, V. C. (2002). Hyaluronan and tumor growth. Am J Pathol 161, 745-747.
126. Toole, B. P., and Slomiany, M. G. (2008). Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 18, 244-250.
127. Trujillo-Santos, J., and Monreal, M. (2011). Anticoagulant use in cancer patients. Expert Opin Pharmacother 12, 351-362.
128. Twarock, S., Tammi, M. I., Savani, R. C., and Fischer, J. W. (2011). Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem 285, 23276-23284.
129. Tyagi, S. C., Kumar, S., and Katwa, L. (1997). Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. Mol Cell Cardiol 29, 391-404.
130. Ueno, M., Uchiyama, K., Ozawa, S., Hayami, S., Kiriyama, S., and Yamaue, H. (2009). A new prediction model of postoperative complications after major hepatectomy for hepatocellular carcinoma. Dig Surg 26, 392-399.
131. Vlodavsky I., Bar-Shavit, R., Korner, G., and Fuks Z. (1993). Extracellular matrix-boundgrowth factors, enzymes and plasma proteins. In Basement membranes: Cellular and Molecular aspects, D. H.Rohrbach and R. Timpl, eds. Orlando, FL: Academic Press, pp. 327-343.
132. Vlodavsky, I., Folkman, J., Sullivan, R., et al. (1987). Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A 84, 2292-2296.
133. Vlodavsky, I., and Friedmann, Y. (2001). Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108, 341-347.
134. Vlodavsky, I., Korner, G., Ishai-Michaeli, R., Bashkin, P., Bar-Shavit, R., and Fuks, Z. (1990). Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9, 203-226.
135. Wang, X., Wang, Y., Yu, L., et al. (2011). CSPG4 in cancer: multiple roles. Curr Mol Med 10, 419-429.
136. Wegrowski, Y., and Maquart, F. X. (2004). Involvement of stromal proteoglycans in tumour progression. Crit Rev Oncol Hematol 49, 259-268.
137. Weigel, P. H., and DeAngelis, P. L. (2007). Hyaluronan synthases: a decade-plus of novel glycosyltransferases. J Biol Chem 282, 36777-36781.
138. Yee, A. J., Akens, M., Yang, B. L., et al. (2007). The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 9, R47.
139. Yin, X., Truty, J., Lawrence, R., et al. (2011). A critical role for lymphatic endothelial heparan sulfate in lymph node metastasis. Mol Cancer 9, 316.
140. Zafiropoulos, A., and Tzanakakis, G. N. (2008). Decorin-mediated effects in cancer cell biology. Connect Tissue Res 49, 244-248.